Does Timing Matter in Gene Therapy for nAMD? - Scorecard - MDSpire

Does Timing Matter in Gene Therapy for nAMD?

Carl C. Awh, MD, FASRS, discusses 2-year phase 2b PRISM results showing durable outcomes with investigational 4D-150 in patients with recently diagnosed neovascular age-related macular degeneration.

  • By

  • Carl C. Awh, MD

  • July 15, 2026

  • 2 min

Share

Clinical Scorecard: Does Timing Matter in Gene Therapy for nAMD?

At a Glance

CategoryDetail
Conditionneovascular age-related macular degeneration (nAMD)
Key Mechanismsgene therapy with investigational 4D-150
Target Populationpatients with recently diagnosed nAMD
Care Settingclinical research setting

Key Highlights

  • 66% of patients went 2 years without additional injections
  • 87% had far fewer injections than standard-of-care aflibercept
  • Majority had 2 or fewer injections over 2 years
  • Excellent maintenance of vision and OCT outcomes
  • Minimal safety concerns with only 2 cases of iritis

Guideline-Based Recommendations

Diagnosis

    Management

    • Consider gene therapy for recently diagnosed nAMD patients

    Monitoring & Follow-up

    • Monitor for potential iritis and other adverse events

    Risks

    • Potential for undertreatment due to injection burden

    Patient & Prescribing Data

    patients with recently diagnosed neovascular age-related macular degeneration

    4D-150 shows promising durability and safety in reducing treatment burden

    Clinical Best Practices

    • Evaluate the potential of gene therapy in managing nAMD
    • Assess patient adherence to treatment regimens

    Related Resources & Content

      Original Source(s)

      Does Timing Matter in Gene Therapy for nAMD?

      • by Carl C. Awh, MD

      • July 15, 2026

      Related Content

      A First Look at Phase 2 ArMaDa Data

      Arshad M. Khanani, MD, FASRS, discusses phase 2 findings for OCU410, an investigational gene therapy for geographic atrophy. A phase 3 program is expected to begin later this year.

      Lessons From the ARCHER Trial

      Margaret A. Chang, MD, MS, discusses how findings from the phase 2 ARCHER trial informed the design of the ongoing phase 3 ARCHER II study of vonaprument, which is expected to read out later this year.

      VesselMetaKAN: vessel-guided meta-learned interpretable classification for diabetic retinopathy grading